The FDA has approved Ilumya (tildrakizumab-asmn) for active psoriatic arthritis in adults based on findings from the phase 3 INSPIRE-1 and INSPIRE-2 trials.

Maternal AD is associated with increased risk for some obstetric and neonatal adverse events, such as pre-eclampsia and Staphylococcal septicemia.

Premature menopause (younger than 40 years) was associated with greater risks for CVD and coronary heart disease compared with menopause at age 45 years or older.

HealthDay News — For pediatric patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL), residential fine particulate matter (PM 2.5) concentrations during induction therapy are associated ...

The FDA granted Priority Review to Qtorin (rapamycin) 3.9% topical gel for microcystic lymphatic malformations, setting a PDUFA action date of Feb 28, 2027.

Dr Waldman discussed social media as a patient education tool, the unforeseen benefits on clinical practice by using TikTok, ...

Ivarmacitinib use for 52 weeks in adolescents and adults with AD was associated with skin clearance, symptom relief, and quality of life improvements.

Patients with psoriasis with obesity are at an increased risk for primary failure of biologic therapies when compared with those without obesity.

Apremilast is effective for the treatment of patients with plaque psoriasis who have limited skin involvement, including in high-impact areas.

Real-world data from Fall Clinical 2026 reveal widespread treatment dissatisfaction, anxiety, and steroid hesitancy among ...

No significant differences were noted in efficacy outcomes associated with upadacitinib vs abrocitinib at 12 weeks of treatment for AD.

The quadrivalent HPV vaccine provides durable immune responses and protects against cervical disease in women with HIV.